Opus Genetics IRD Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage

Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage at other companies

Quantum Computing Inc.QUBT

20%0.0pp

Lincoln Educational Services CorporationLINC

50%—

Quantum Computing Inc.QUBT

25K—

U.S. BancorpUSB

9.3M+0.4%

Lesaka Technologies, Inc.LSAK

2.6M-8.4%

SBA CommunicationsSBAC

14K-30.0%

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's sharebased compensation arrangement by sharebased payment award award vesting rights percentage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's sharebased compensation arrangement by sharebased payment award award vesting rights percentage?: Opus Genetics (IRD) reported sharebased compensation arrangement by sharebased payment award award vesting rights percentage of 100% in Q1 2026.